Flexion Therapeutics

As a highly focused specialty pharmaceutical team, our goal is to cost effectively develop and commercialize novel therapies that will provide safe, substantial and sustained pain relief to the sufferers of musculoskeletal (MSK) diseases, the first of which is OA. We focus on product candidates that have the potential to provide long-lasting analgesia locally while avoiding systemic side effects. We also aim to:
Type
Public
HQ
Burlington, US
Founded
2007
Size (employees)
48 (est)
Flexion Therapeutics was founded in 2007 and is headquartered in Burlington, US

Key People at Flexion Therapeutics

Mike Clayman

Mike Clayman

Chief Executive Officer & Co-Founder
Neil Bodick

Neil Bodick

Chief Medical Officer & Co-Founder

Flexion Therapeutics Office Locations

Flexion Therapeutics has an office in Burlington
Burlington, US (HQ)
301 10 Burlington Mall Road

Flexion Therapeutics Data and Metrics

Flexion Therapeutics Financial Metrics

Flexion Therapeutics's revenue was reported to be $0 in FY, 2015
Numbers are in $, USD

Net income (FY, 2016)

(71.9 m)

EBIT (FY, 2016)

(69.8 m)

Market capitalization (24-May-2017)

614.5 m

Closing share price (24-May-2017)

19.6

Cash (31-Dec-2016)

30.9 m

EV

614.1 m
Flexion Therapeutics's current market capitalization is $614.5 m.
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Revenue

R&D expense

17.9 m32.7 m41.3 m

General and administrative expense

9.1 m13.4 m28.5 m

Operating expense total

27 m46.1 m69.8 m

EBIT

(27 m)(46.1 m)(69.8 m)

Interest expense

(401.4 k)(571 k)(1.7 m)

Interest income

478.7 k1.2 m1.5 m

Net Income

(27.3 m)(46.3 m)(71.9 m)
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Cash

103.1 m62.9 m30.9 m

Accounts Receivable

95.3 k55.8 m

Inventories

502.3 k760.9 k3.8 m

Current Assets

152.1 m112.1 m209.4 m

PP&E

1.1 m7.4 m11.7 m

Total Assets

153.4 m127.1 m226.3 m

Accounts Payable

1.6 m3.7 m2.2 m

Total Debt

3.6 m17 m30.5 m

Current Liabilities

6.8 m8.1 m17.5 m

Additional Paid-in Capital

238.4 m243.9 m398.8 m

Retained Earnings

(93.5 m)(139.8 m)(211.7 m)

Total Equity

144.9 m104 m187 m

Debt to Equity Ratio

0 x0.2 x0.2 x

Debt to Assets Ratio

0 x0.1 x0.1 x

Financial Leverage

1.1 x1.2 x1.2 x
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Net Income

(27.3 m)(46.3 m)(71.9 m)

Depreciation and Amortization

120.3 k238.2 k1.2 m

Accounts Receivable

95.3 k

Inventories

(9.1 m)46.9 m(34 m)

Accounts Payable

518 k1.6 m(992.7 k)

Cash From Operating Activities

(23.1 m)(38.9 m)(62.5 m)

Purchases of PP&E

(802.5 k)(5.2 m)(8.4 m)

Cash From Investing Activities

(49.5 m)(13.2 m)(132.8 m)

Cash From Financing Activities

159.5 m12 m163.2 m

Interest Paid

364.9 k572.3 k1.3 m
Y, 2016

EV/EBIT

-8.8 x

EV/CFO

-9.8 x

Debt/Equity

0.2 x

Debt/Assets

0.1 x

Financial Leverage

1.2 x

Flexion Therapeutics Market Value History

Flexion Therapeutics Online and Social Media Presence

Flexion Therapeutics Company Life and Culture

You may also be interested in